These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 12606940

  • 1. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
    Zeng PY, Rane N, Du W, Chintapalli J, Prendergast GC.
    Oncogene; 2003 Feb 27; 22(8):1124-34. PubMed ID: 12606940
    [Abstract] [Full Text] [Related]

  • 2. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
    Du W, Lebowitz PF, Prendergast GC.
    Mol Cell Biol; 1999 Mar 27; 19(3):1831-40. PubMed ID: 10022870
    [Abstract] [Full Text] [Related]

  • 3. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.
    Oncogene; 2003 Jun 05; 22(23):3578-88. PubMed ID: 12789266
    [Abstract] [Full Text] [Related]

  • 4. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
    Du W, Prendergast GC.
    Cancer Res; 1999 Nov 01; 59(21):5492-6. PubMed ID: 10554025
    [Abstract] [Full Text] [Related]

  • 5. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar 01; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep 01; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 7. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM.
    Oncogene; 2002 Nov 07; 21(51):7883-90. PubMed ID: 12420225
    [Abstract] [Full Text] [Related]

  • 8. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors.
    Liu Ax, Du W, Liu JP, Jessell TM, Prendergast GC.
    Mol Cell Biol; 2000 Aug 07; 20(16):6105-13. PubMed ID: 10913192
    [Abstract] [Full Text] [Related]

  • 9. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors.
    Liu A, Prendergast GC.
    FEBS Lett; 2000 Sep 22; 481(3):205-8. PubMed ID: 11007964
    [Abstract] [Full Text] [Related]

  • 10. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors.
    Du W, Lebowitz PF, Prendergast GC.
    Cancer Res; 1999 May 01; 59(9):2059-63. PubMed ID: 10232587
    [Abstract] [Full Text] [Related]

  • 11. The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells.
    Kim HS, Kim JW, Gang J, Wen J, Koh SS, Koh JS, Chung HH, Song SY.
    Toxicol Appl Pharmacol; 2006 Sep 15; 215(3):317-29. PubMed ID: 16712893
    [Abstract] [Full Text] [Related]

  • 12. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB.
    Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA.
    J Biol Chem; 1997 Jun 20; 272(25):15591-4. PubMed ID: 9188444
    [Abstract] [Full Text] [Related]

  • 13. Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase.
    Wherlock M, Gampel A, Futter C, Mellor H.
    J Cell Sci; 2004 Jul 01; 117(Pt 15):3221-31. PubMed ID: 15226397
    [Abstract] [Full Text] [Related]

  • 14. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.
    van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD.
    Mol Cancer Ther; 2002 Jun 01; 1(8):575-83. PubMed ID: 12479217
    [Abstract] [Full Text] [Related]

  • 15. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity.
    Lebowitz PF, Davide JP, Prendergast GC.
    Mol Cell Biol; 1995 Dec 01; 15(12):6613-22. PubMed ID: 8524226
    [Abstract] [Full Text] [Related]

  • 16. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW.
    Br J Haematol; 2005 Sep 01; 130(6):912-25. PubMed ID: 16156861
    [Abstract] [Full Text] [Related]

  • 17. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
    Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD, Sebti SM.
    J Biol Chem; 1995 Nov 10; 270(45):26802-6. PubMed ID: 7592920
    [Abstract] [Full Text] [Related]

  • 18. Ras, but not Src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade.
    Oldham SM, Cox AD, Reynolds ER, Sizemore NS, Coffey RJ, Der CJ.
    Oncogene; 1998 May 10; 16(20):2565-73. PubMed ID: 9632133
    [Abstract] [Full Text] [Related]

  • 19. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
    Du J, Jiang B, Coffey RJ, Barnard J.
    Mol Cancer Res; 2004 Apr 10; 2(4):233-41. PubMed ID: 15140945
    [Abstract] [Full Text] [Related]

  • 20. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death.
    Ader I, Toulas C, Dalenc F, Delmas C, Bonnet J, Cohen-Jonathan E, Favre G.
    Oncogene; 2002 Sep 05; 21(39):5998-6006. PubMed ID: 12203112
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.